Jason McCarthy: I will break it down into therapeutic categories, because they are different. If we look at the stem cell therapy space, which I described earlier as being a laggard in terms of valuation as compared to CAR-T and gene therapy, you can include Cytori Therapeutics Inc. (CYTX:NASDAQ), Athersys Inc. (ATHX:NASDAQ), Mesoblast Ltd. (MESO:NASDAQ; MSB:ASX) and BrainStorm Cell Therapeutics Inc. (BCLI:NASDAQ), as well as Capricor Therapeutics (CAPR:NASDAQ).